{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:59:16Z","timestamp":1793174356242,"version":"4.5.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lanepe.2024.101100","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T03:59:48Z","timestamp":1731124788000},"page":"101100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Recent achievements and future directions of anti-obesity medications"],"prefix":"10.1016","volume":"47","author":[{"given":"Gerald","family":"Grandl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-001X","authenticated-orcid":false,"given":"Aaron","family":"Novikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-9339","authenticated-orcid":false,"given":"Timo D.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2024.101100_bib1","series-title":"WHO European regional obesity report 2022","year":"2022"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101100_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dme.13609","article-title":"Continuing rise of Type 2 diabetes incidence in children and young people in the UK","volume":"35","author":"Candler","year":"2018","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Collaborators GBDO","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.lanepe.2024.101100_bib5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101100_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.lanepe.2024.101100_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10278","key":"10.1016\/j.lanepe.2024.101100_bib8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10295","key":"10.1016\/j.lanepe.2024.101100_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101100_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10401","key":"10.1016\/j.lanepe.2024.101100_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101100_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A\u00a0GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"issue":"10403","key":"10.1016\/j.lanepe.2024.101100_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2024.101100_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101100_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/00365529609009147","article-title":"Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day","volume":"31","author":"Orskov","year":"1996","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00125-005-1705-7","article-title":"Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors","volume":"48","author":"Holst","year":"2005","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jdiacomp.2014.12.006","article-title":"Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide","volume":"29","author":"Kuhre","year":"2015","journal-title":"J\u00a0Diabetes Complications"},{"issue":"10","key":"10.1016\/j.lanepe.2024.101100_bib19","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"10.1016\/j.lanepe.2024.101100_bib20","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101100_bib21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib22","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101100_bib23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/diacare.19.6.580","article-title":"Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients","volume":"19","author":"Creutzfeldt","year":"1996","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"12","key":"10.1016\/j.lanepe.2024.101100_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101100_bib26","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101100_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahren","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101100_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101100_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9683","key":"10.1016\/j.lanepe.2024.101100_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"9662","key":"10.1016\/j.lanepe.2024.101100_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.lanepe.2024.101100_bib34","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.lanepe.2024.101100_bib35","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101100_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101100_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.lanepe.2024.101100_bib41","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.lanepe.2024.101100_bib42","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101100_bib43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metabol"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101100_bib44","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metabol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metabol"},{"issue":"12","key":"10.1016\/j.lanepe.2024.101100_bib46","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat Metab"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101100_bib47","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metabol"},{"key":"10.1016\/j.lanepe.2024.101100_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101945","article-title":"Stimulating intestinal GIP release reduces food intake and body weight in mice","volume":"84","author":"Lewis","year":"2024","journal-title":"Mol Metab"},{"issue":"Pt B","key":"10.1016\/j.lanepe.2024.101100_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","volume":"136","author":"Holscher","year":"2018","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib50","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41574-024-01000-z","article-title":"Gut hormones and bone homeostasis: potential therapeutic implications","volume":"20","author":"Bouvard","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.lanepe.2024.101100_bib51","doi-asserted-by":"crossref","first-page":"E2325","DOI":"10.1210\/jc.2014-2547","article-title":"Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans","volume":"99","author":"Nissen","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.lanepe.2024.101100_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116065","article-title":"Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: a preliminary study","volume":"152","author":"Skov-Jeppesen","year":"2021","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib53","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1210\/jc.2017-01949","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia","volume":"103","author":"Christensen","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.lanepe.2024.101100_bib54","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A\u00a0new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"209","key":"10.1016\/j.lanepe.2024.101100_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.lanepe.2024.101100_bib56","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.lanepe.2024.101100_bib57","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1111\/dom.15875","article-title":"A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy","volume":"26","author":"Knop","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101100_bib58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10300","key":"10.1016\/j.lanepe.2024.101100_bib59","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101100_bib60","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"10313","key":"10.1016\/j.lanepe.2024.101100_bib61","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.lanepe.2024.101100_bib62","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib63","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib64","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","article-title":"Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101100_bib65","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat Med"},{"issue":"10402","key":"10.1016\/j.lanepe.2024.101100_bib66","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lanepe.2024.101100_bib67","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101100_bib69","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"Muller","year":"2017","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib71","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/jdi.14032","article-title":"Blockade of glucagon increases muscle mass and alters fiber type composition in mice deficient in proglucagon-derived peptides","volume":"14","author":"Ueno","year":"2023","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.lanepe.2024.101100_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clnesp.2021.06.025","article-title":"The effects of glucagon and the target of rapamycin (TOR) on skeletal muscle protein synthesis and age-dependent sarcopenia in humans","volume":"44","author":"Adeva-Andany","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.lanepe.2024.101100_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib74","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bluher","year":"2024","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib75","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib76","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A\u00a0phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.lanepe.2024.101100_bib77","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0167-0115(88)90099-7","article-title":"Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs","volume":"21","author":"Baldissera","year":"1988","journal-title":"Regul Pept"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101100_bib78","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1210\/endo.133.2.8102095","article-title":"Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line","volume":"133","author":"Gros","year":"1993","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101100_bib79","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.gastro.2004.04.063","article-title":"Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure","volume":"127","author":"Baggio","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A\u00a0rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib81","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A\u00a0phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib82","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A\u00a0phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-Gomez","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.lanepe.2024.101100_bib83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"issue":"10366","key":"10.1016\/j.lanepe.2024.101100_bib84","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101100_bib85","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101100_bib86","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell Rep Med"},{"issue":"10","key":"10.1016\/j.lanepe.2024.101100_bib87","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.lanepe.2024.101100_bib88","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2024.101100_bib89","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2024","journal-title":"J\u00a0Endocr Soc"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib90","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lanepe.2024.101100_bib91","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.lanepe.2024.101100_bib92","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.lanepe.2024.101100_bib93","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure","volume":"75","author":"Marso","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib94","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10193","key":"10.1016\/j.lanepe.2024.101100_bib95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.lanepe.2024.101100_bib96","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.lanepe.2024.101100_bib97","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10157","key":"10.1016\/j.lanepe.2024.101100_bib98","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib99","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.lanepe.2024.101100_bib100","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101100_bib101","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/j.gastro.2017.12.024","article-title":"Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis","volume":"154","author":"Khera","year":"2018","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.lanepe.2024.101100_bib102","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"10437","key":"10.1016\/j.lanepe.2024.101100_bib103","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib104","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101100_bib105","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.lanepe.2024.101100_bib106","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.lanepe.2024.101100_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib108","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib109","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/dom.14215","article-title":"Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice","volume":"23","author":"Sachs","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.lanepe.2024.101100_bib110","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib111","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1253\/circj.CJ-16-0152","article-title":"Suppressive effects of glucose-dependent insulinotropic polypeptide on cardiac hypertrophy and fibrosis in Angiotensin II-infused mouse models","volume":"80","author":"Hiromura","year":"2016","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101100_bib112","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cmet.2017.11.003","article-title":"Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction","volume":"27","author":"Ussher","year":"2018","journal-title":"Cell Metabol"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib113","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib114","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ejn.14096","article-title":"Post hoc analysis of the Exenatide-PD trial-Factors that predict response","volume":"49","author":"Athauda","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.lanepe.2024.101100_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","volume":"73","author":"Tang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.lanepe.2024.101100_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102019","article-title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice","author":"Forny Germano","year":"2024","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.lanepe.2024.101100_bib118","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.lanepe.2024.101100_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.lanepe.2024.101100_bib120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26 Suppl 4","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib121","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101100_bib122","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00421-003-0991-3","article-title":"Muscle strength, power and adaptations to resistance training in older people","volume":"91","author":"Macaluso","year":"2004","journal-title":"Eur J Appl Physiol"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101100_bib123","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/oby.22393","article-title":"Body fat loss automatically reduces lean mass by changing the fat-free component of adipose tissue","volume":"27","author":"Abe","year":"2019","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib124","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1152\/ajpendo.2002.282.1.E132","article-title":"Body-size dependence of resting energy expenditure can be attributed to nonenergetic homogeneity of fat-free mass","volume":"282","author":"Heymsfield","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.lanepe.2024.101100_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101100_bib126","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35797","article-title":"Sodium-glucose cotransporter 2 inhibitors vs incretin-based drugs and risk of fractures for type 2 diabetes","volume":"6","author":"Ko","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib127","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101100_bib128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13679-023-00539-8","article-title":"The physiological effects of weight-cycling: a review of current evidence","volume":"13","author":"Sanaya","year":"2024","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.lanepe.2024.101100_bib129","doi-asserted-by":"crossref","first-page":"101098","DOI":"10.1016\/j.lanepe.2024.101098","article-title":"Why are we still in need for novel anti-obesity medications?","volume":"47","author":"Novikoff","year":"2024","journal-title":"Lancet Reg Health Eur"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224002679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224002679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:14:55Z","timestamp":1733480095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776224002679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":129,"alternative-id":["S2666776224002679"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101100","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent achievements and future directions of anti-obesity medications","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101098","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101100"}}